Interleukin Genetics Inc.

Lewis H. Bender served as President and Chief Executive Officer from January 12, 2007 through Mr. Novinski s appointment. Mr. Bender then served as Chief Technology Officer through December 7, 2007. Included in all other compensation for Mr. Bender in 2007 are severance payments of $13,677 and matching contributions made under a defined contribution plan available to substantially all employees of $9,000. Included in all other compensation for Mr. Bender in 2006 are $8,800 in matching contributions made under a defined contribution plan available to substantially all employees.

Todd Anthony Walker joined Interleukin Genetics, Inc. as Vice President, Marketing in December 2008. Mr. Walker brings to the firm extensive marketing experience, as well as 20 years of industry-related experience. Prior to joining Interleukin Genetics, Mr. Walker was the Worldwide Marketing Director for the Biopatch and OMNEX and synthetic sealants for Johnson & Johnson (JNJ) having worked in the Ethicon Inc., Jansen, Ortho-McNeil and PSGA divisions. Mr. Walker was responsible for developing global marketing strategies, establishing and influencing regional launches for products and building the framework for multigenerational product plans. Prior to joining Johnson & Johnson, Mr. Walker worked as a manager in various capacities with the Procter & Gamble Company. Mr. Walker holds a Masters of Business Administration from Duke University's FUQUA School of Business, and a Bachelor's of Science Electrical Engineering Degree from Union College in Schenectady, New York.

Ramon W. Mohanlal, MD, PhD, MBA, is a physician with specialist training in internal medicine and cardiology and has 12 years of experience in the biopharmaceutical industry. He is an officer of the company and currently holds the position of Chief Medical Officer. Prior to joining Interleukin Geneticsin July 2005, Dr. Mohanlal spent three and a half years as Medical Director at Vertex Pharmaceuticals, Inc, where he was responsible for developing its anti-inflammatory drug portfolio. He was co-founder of, and served as acting CEO and Director of Research and Development at Syncytium, Inc. Prior to that, he worked for Pharmacia and GlaxoWellcome in clinical drug development positions of increasing managerial seniority . He holds a MD and PhD (Cardiology) from the University of Leiden, The Netherlands. He obtained a MBA from AIU and attended the greater Boston executive management program at the MIT/Sloan School of Management.

Emad El-Omar MD, is an expert in genetics and the risk and management of gastrointestinal cancers. His work has led to the understanding that inflammation in the stomach caused by Helicobacter pylori infection - the bacterial infection implicated in GI ulcers and also considered the primary risk factor in gastric cancer - is excessive in people with specific IL-1 genetic variations. The excess inflammation appears to lead to decreased stomach acid and atrophy of the gastric mucosa (tissue lining the stomach), leading to cancerous changes. Dr. El-Omar is Professor and Chair of Gastroenterology and leader of the Biology of Cancer Theme within the Institute of Medical Sciences, Aberdeen University, Scotland. He was previously at the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland. In 2000, Professor El-Omar published a landmark paper (Nature 2000 404:398-402) describing the role of interleukin-1 genetic variations in gastric cancer. Since that time, investigators have confirmed his findings in over 20 studies. His current research focuses primarily on the role of inflammation in GI cancers.

George D. Calvert is the Vice President, Research & Development/Quality Assurance of Access Business Group LLC, a manufacturing and distribution company and wholly owned subsidiary of Alticor Inc. He has held this position for the past five years. Dr. Calvert has previously held the positions of Director Quality Assurance/Analytical Services with Access Business Group LLC, and Senior Manager Home Tech Research & Development with Amway Corporation. Dr. Calvert earned a Ph.D. in Analytical Chemistry from the University of South Carolina and a Bachelor of Science degree in Chemistry from the College of William and Mary. He joined the Board of Directors as a Series A Director effective March 24, 2003.

Jose Ordovas, PhD, is Professor of Nutrition, Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University and Professor of Genetics, Sackler School of Biomedical Sciences and the Director. He is also senior scientist and Director of the Nutrition and Genomics Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA), one of six human nutrition research centers in the United States supported by the Agricultural Research Service (ARS), the research arm of the United States Department of Agriculture (USDA). His research focus includes molecular biology, nutrition and genetics; and lipoproteins and cardiovascular disease risk. An extensive author and lecturer, Dr. Ordovas is an internationally recognized expert in the intersection of genetics, cardiovascular disease, nutrition, and aging. He has over 400 publications, including original science, reviews, books and book chapters.